Insulin resistance in obese patients with type 2 diabetes mellitus : effects of a very low calorie diet

Jazet, I.M.

CHAPTER 2

Adipose tissue as an endocrine organ: impact on insulin resistance

Ingrid M. Jazet, Hanno Pijl, A.E. Meinders

Department of General Internal Medicine, Leiden University Medical Centre, Leiden, The Netherlands

The Netherlands Journal of Medicine 2003;61(6):194-212

ABSTRACT

It is well known that obesity is associated with insulin resistance and an increased risk for type 2 diabetes mellitus. Formerly it was postulated that increased lipolysis and consequently free fatty acid (FFA) production, from with triglycerides overloaded fat cells would disrupt glucose homeostasis *via* Randle's hypothesis. Lipodystrophy, however, also leads to insulin resistance. Recently it has become clear that adipose tissue functions as an endocrine organ and secretes numerous proteins in response to a variety of stimuli. These secreted proteins exert a pleiotropic effect. The proteins that are involved in glucose and fat metabolism and, hence, can influence insulin resistance are discussed in this paper. They include leptin, resistin, adiponectin, acylation-stimulating protein, tumour necrosis factor-α and interleukin-6. The stimuli for production and the site and mechanism of action in relation to insulin resistance will be discussed. None of these proteins are, however, without controversy with regard to their mechanism of action. Furthermore, some of these proteins may influence each other *via* common signalling pathways. A theory is presented to link the interrelationship between these adipocyte secretory products and their effect on insulin resistance.

INTRODUCTION

Type 2 diabetes mellitus is a chronic disease characterised by insulin resistance of the muscle, liver and adipose tissue and an impaired function of the β-cell of the pancreas[1].

The incidence of type 2 diabetes mellitus (type 2 DM) has increased dramatically over the last decades. Nowadays it is the most frequently occurring metabolic disease, affecting over 140 million people worldwide with an expected rise to about 300 million patients in 2025[2]. Epidemiological studies assessing the explanation for this explosion point to an excess caloric intake over metabolic demand and decreased physiological activity as plausible causes. A chronic imbalance between energy intake and energy expenditure eventually leads to obesity, a condition predisposing to insulin resistance and type 2 DM. Of type 2 diabetic patients, 80% are overweight or obese, as defined by a body mass index > 25 and 30 kg/m^2, respectively[3].

In the past, adipose tissue was merely viewed as a passive organ for storing excess energy in the form of triglycerides. Recently, however, it has become clear that the adipocyte actively regulates the pathways responsible for energy balance and that this function is controlled by a complex network of hormonal and neuronal signals.

To discuss all the adipocyte secretory products (Table 1) and all their effects is beyond the scope of this paper. In this review we will focus on the function of the adipocyte in relation to

Table 1. Proteins secreted by adipocytes.

Molecule	Effect
Leptin*	Feedback effect on hypothalamic energy regulation; maturation of reproductive function
Resistin*	Appears to impair insulin sensitivity
Adiponectin*	Improves insulin sensitivity if administered to rodent models of insulin resistance; improves fatty acid transport and utilization
Adipsin*	Required for the synthesis of ASP, possible link between activation of the complement pathway and adipose tissue metabolism.
ASP*	Activates diacylglycerol acyltransferase, inhibits hormone sensitive lipase, stimulates GLUT-4 translocation to the cell surface.
TNF-α*	Mediator of the acute phase response. Inhibits lipogenesis, stimulates lipolysis and impairs insulin-induced glucose uptake, thus leading to insulin resistance and weight loss.
IL-6*	Increases hepatic glucose production and triglyceride synthesis, role in insulin resistance unclear
PAI-1	Potent inhibitor of the fibrinolytic system
Tissue factor	Initiator of the coagulation cascade
Angiotensinogen	Regulator of blood pressure and electrolyte homeostasis.
PGI_2 and $PGF_2\alpha$	Implicated in inflammation and blood clotting, ovulation and menstruation, acid secretion
TGF-β	Regulates growth and differentiation of numerous cell types
IGF-1	Stimulates cell proliferation and mediates many of the effects of growth hormone
MIF	Involved in proinflammatory processes and immunoregulation
aP_2	Involved in intracellular trafficking and targeting of fatty acids
agouti	Might be involved in inducing insulin resistance through increasing intracellular free calcium concentrations

Proteins discussed in this chapter.

insulin resistance and obesity. Firstly, the differentiation process of the adipocyte will be discussed. Then, some of the adipocyte secretory products that are involved in energy balance regulation and their function will be considered. Finally, some interactions between adipocyte-derived factors that could be involved in inducing insulin resistance will be described.

ADIPOCYTE DIFFERENTIATION

There are two forms of adipose tissue: white adipose tissue (WAT) and brown adipose tissue (BAT). BAT serves primarily to dissipate energy, which is done *via* uncoupling protein 1 (UCP-1) in the mitochondria of BAT. Adult humans have only a small amount of BAT. WAT stores energy in the form of triglycerides. It has recently become evident that WAT also secretes a vast amount of so-called adipocytokines, which are involved in maintaining energy homeostasis. This will be discussed in this article.

In humans, the formation of WAT begins during late embryonic development, with a rapid expansion shortly after birth as a result of increased fat cell size as well as fat cell number. Even in adults the potential to generate new fat cells persists. The origin of the adipose cell and adipose tissue are still poorly understood. Our current understanding indicates that a pluripotent stem cell precursor gives rise to a mesenchymal precursor cell, which has the potential to differentiate along mesodermal lineages of myoblast, chondroblast, osteoblast and adipocyte (Fig. 1)[4]. Given appropriate stimuli the preadipocyte undergoes clonal expansion and subsequent terminal differentiation into a mature adipocyte.

In vitro, adipogenesis follows an orderly and well-characterised temporal sequence[4,5]. Initially there is growth arrest of proliferating preadipocytes induced by the addition of a pro-differentiative hormonal mixture (including insulin, a glucocorticoid, an agent that elevates cAMP levels and fetal bovine serum). Growth arrest is followed by one or two rounds of cell division, known as clonal expansion. At about the second day after differentiation induction there is a second, permanent period of growth arrest. Growth-arrested cells are committed to becoming adipocytes and begin to express late markers of adipocyte differentiation at day 3. Cells eventually become spherical, accumulate fat droplets and become terminally differentiated adipocytes by day 5 to 7.

Most of the changes that occur during adipocyte differentiation take place at the gene expression level. Several reports[4,5] have attempted to schematise the stages of adipocyte differentiation as we have here in Fig. 1.

Three major classes of transcription factors that directly influence fat cell development have been identified: the peroxisome proliferator-activated receptor-γ (PPAR-γ), CCAAT/enhancer binding proteins (C/EBPs) and the basic helix-loop-helix family (ADD1/SREBP1c).

The C/EBPs belong to the basic-leucine zipper class of transcription factors which function through homodimeric and heterodimeric complexes with C/EBP family members. Six



Figure 1.

Addition of mitogens and hormonal stimuli to 3T3-L1 cells leads to a cascade of transcriptional events that account for the expression of most proteins mediating adipocyte function. See text on page 58 to 60 for further explanation.

isoforms have been identified with varying tissue distribution. C/EBP α, β and δ are expressed in both white and brown adipose tissue and are involved in the regulation of adipogenesis[5].

The peroxisome proliferator-activated receptor (PPAR) belongs to the nuclear hormone receptor family. Three isotypes have been identified thus far, PPPAR α, β and γ, each with a different tissue distribution, ligand and metabolic action. All PPARs form a heterodimer with the retinoid X receptor (RXR) and bind to a PPAR-RXR response element on the DNA. Their actions upon ligand binding, however, are completely different. PPAR-γ exists as three isoforms, γ1, γ2 and γ3. PPAR-γ2 is highly expressed in adipose tissue. The thiazolidinediones (TZDs, a new class of oral blood glucose-lowering drugs), which are high affinity synthetic ligands for PPAR-γ, strongly induce adipogenesis and activate the expression of multiple genes encoding for proteins involved in lipid and glucose metabolism[6,7].

Adipocyte determination and differentiation factor 1(ADD1) and sterol regulatory element binding protein 1c (SREBP-1c), which are rodent and human homologues respectively, belong to the basic helix-loop-helix (bHLH) family of transcription factors. ADD1/SREBP1c is expressed in brown adipose tissue, the liver, WAT and the kidney[5]. The expression of ADD1-SREBP-1c is increased early during adipocyte differentiation[4,5]. The protein seems to exert its adipogenic effect through upregulation of PPAR-γ. Furthermore the protein might be involved in the production of an endogenous ligand for PPAR-γ[8]. In addition to its effect on adipogenesis, ADD1/SREBP-1c clearly stimulates many genes involved in fatty acid and cholesterol metabolism[9].



Figure 2.

Figure 2[4,5].

Solid lines indicate direct or indirect transcriptional events. Broken lines indicate less clear interactions. The addition of prodifferentiative agents to 3T3-L1 cells leads to a significant and transient increase of the transcription factors C/EBP β and δ, which in turn mediate the expression of another transcription factor: PPAR-γ. PPAR-γ is also activated by ADD1/SREBP$_{1c}$[8] although the events leading to the activation of ADD1/SREBP$_{1c}$ are not fully understood. PPAR-γ on turn activates C/EBP-α, these two proteins seem to cross regulate each other, thus maintaining their gene expression despite a decline in C/EBP β and δ. Activation of PPAR-γ and C/EBP α leads to the expression of many adipocyte specific proteins involved in glucose and lipid metabolism (LPL, aP2, fatty acid synthase, etc.), adipocyte differentiation and an increase in insulin sensitivity, either via a decrease in triglycerides and fatty acids or via a direct effect on proteins involved in glucose metabolism (PEPCK, GLUT-4).

A summary of the molecular events of adipocyte differentiation, based on our current knowledge, is depicted in Fig. 1 and 2.

ADIPOCYTE SECRETORY PRODUCTS

Leptin

Discovery, structure, genetic locus and sites of expression of leptin

The discovery of leptin (from the Greek *leptos* which means thin) in 1994[10] has led to a renewed and intensified interest in the adipocyte and its role in energy homeostasis. Leptin acts on hypothalamic neuropeptide-containing regions and increased leptin signalling leads to decreased food intake, increased energy expenditure and increased thermogenesis, all promoting weight loss. Apart from these effects, leptin is also involved in glucose metabolism, normal sexual maturation and reproduction, and has interactions with the hypothalamic-pituitary-adrenal, thyroid and growth hormone axes.

Leptin is a protein consisting of 167 amino acids and has a helical structure similar to cytokines. Leptin is the product of the *ob* gene, which is located on chromosome 7q31. Leptin

is expressed mainly in white adipose tissue. The protein circulates as both free and bound hormone and is cleared among others by the kidneys[11-13].

Modulators of leptin production[12,13]

Leptin levels are positively correlated with the amount of energy stored as fat, so leptin levels are higher in obese people[14,15]. Leptin levels rapidly decrease during fasting[16] and remain low until four to six hours after eating when they begin to rise again[17]. Plasma leptin levels show a diurnal pattern with a nocturnal peak shortly after midnight and a midmorning through between 10 AM and 12 noon[18]. Insulin also plays a role in the regulation of leptin secretion: prolonged insulin infusions markedly increase leptin levels[19,20]. Finally, even after adjustment for body fat mass, women have higher leptin levels than men[15]. At the gene promotor level, it is known that stimulation of PPAR-γ downregulates leptin production[21] whereas C/EBP-α stimulates leptin production[22].

Site of action of leptin and its role as part of an adipostat

Leptin acts through binding at and activation of specific leptin receptor isoforms, which belong to the class I cytokine receptor family[23]. Only the long isoform (*ob-rb*) is able to activate the JAK-(Janus kinase)-STAT (signal transducers and activators of transcription) signal transduction pathway upon leptin binding (Fig. 3). The long form of the leptin receptor is found in several peripheral tissues and in many areas of the brain, including the arcuate, ventromedial and dorsomedial hypothalamic nuclei[24]. These hypothalamic regions are known to be involved in the regulation of appetite, food intake, temperature regulation and body weight. Intracerebral administration of leptin alters the expression of many hypothalamic neuropeptides[25]. By modulating these neurotransmitter systems, leptin has a major role in maintaining energy balance and thus serves as part of an adipostat. During fasting, serum insulin levels fall and the uptake of glucose and lipids by the adipocyte diminishes. This leads to a decreased expression of the *ob*-gene, which is responsible for leptin formation and, hence, the plasma leptin concentration falls. Reduced leptin signalling leads to an increased expression of neuropeptide Y (NPY) and agouti-related protein (AgRP) in the arcuate nucleus of the hypothalamus. NPY and AgRP promote body weight gain by stimulating food intake and decreasing energy expenditure. Another neuronal cell type co-produces cocaine-amphetamine related transcript (CART) and pro-opiomelanocortin (POMC), from which α-melanocyte stimulating hormone (α-MSH) is cleaved. CART and α-MSH are both anorexigens and reduced leptin signalling inhibits the synthesis of CART and POMC (Fig. 4)[26,27]. Finally, corticotropin-releasing hormone (CRH), which is also produced in the hypothalamus, might be important in mediating the effects of leptin, presumably *via* activation of sympathetic outflow to BAT, WAT, liver and muscle. Intracerebral injection of CRH stimulates thermogenesis and oxygen consumption and reduces food intake and body weight. CRH mRNA levels are increased by the intraventricular administration of leptin[28].



Figure 3.

The leptin receptor is a transmembrane receptor belonging to the class I cytokine receptors. The receptor consists of two parts. The intracellular domain is associated with the Janus kinase, a tyrosine kinase. Binding of leptin to the receptor results in the fusion of the two receptor parts, which results in trans-phosphorylation of the JAK-molecules, which subsequently phosphorylate the terminus of the leptin receptor. The phosphorylated receptor then forms a docking site for a variety of Src homology 2 (SH2) domain containing proteins, including a novel family of cytoplasmatic transcription factors termed STATs (signal transducers and activators of transcription). STATs are then phosphorylated on a single tyrosine residue by JAKs, after which STATs dimerise, migrate to the nucleus and regulate gene transcription.

Role of leptin in obesity

The initial conception of leptin as an anti-obesity hormone, whose primary role was to increase the metabolic rate and decrease food intake and appetite through action in the brain, was based on the following observations: (i) leptin deficient *ob/ob* mice and leptin receptor deficient *db/db* mice exert marked hyperphagia, decreased energy expenditure, morbid obesity and insulin resistance[29,30]; (ii) administration of intravenous or intracerebroventricular leptin decreases body weight and fat mass through inhibition of food intake and increased energy expenditure in *ob/ob* but not in *db/db* mice[31]; (iii) there is a threshold level of serum leptin (25-30 ng/mL) above which increases in serum levels are not translated into proportional increases in cerebrospinal or brain leptin levels, i.e., the transport system must be saturable[32]; (iv) the discovery of leptin receptors in the hypothalamus, the region involved in regulation of food intake and energy balance[27].

However, in most obese humans the gene encoding leptin is normal: up till now only two families with a mutation in the leptin gene have been identified[33,34]. In contrast, most obese humans have increased serum leptin levels[14,15], indicating that obesity is a leptin-resistant



Figure 4.

Starvation leads to a decrease in serum insulin levels and a decreased expression of the *ob*-gene leading to a decrease in serum leptin levels. This subsequently leads to an increased expression of neuropeptide-Y (NPY) and agouti-related protein (AgRP) in the hypothalamus and a decrease in pro-opiomelanocortin (POMC) and cocaine-amphetamine related transcript (CART) in the hypothalamus. These hormones are involved in food intake and energy expenditure, leading to an increase in food intake and a decrease in energy expenditure. Furthermore, the hypothalamic hormones have either a direct or an indirect (via corticotropin-releasing hormone [CRH] and α-melanocyte-stimulating hormone [α-MSH]) effect on various hormones secreted by the pituitary. Thus, leptin has multiple effects, not only on food intake and energy metabolism but also on the hypothalamic-pituitary-adrenal axis, thyroid function and sex steroids.

state. Such a resistance could theoretically occur at several levels of the leptin signal transduction pathway, but this has not been resolved yet.

Leptin and insulin resistance

Since obesity is associated with insulin resistance, it is interesting to look at the role of leptin in the development of insulin resistance and diabetes. A strong correlation between serum leptin and insulin levels, independent of body fatness, has been demonstrated in human studies[35,36]. Hyperinsulinaemia induced by clamp techniques increases serum leptin levels, though not acutely[19]. Serum leptin levels are increased by insulin therapy as well, both in type 1 and type 2 diabetic patients[36,37]. Vice versa, a fair amount of evidence points to the fact that leptin has insulin- and glucose-lowering properties, although some studies find just the opposite. An extensive review on the association between leptin and insulin resistance has recently been published[38].

In both normal rodents[39] and rodents with obesity and insulin resistance[40-42], leptin therapy improves hyperinsulinaemia and hyperglycaemia. These effects are already apparent before weight loss occurs and are not due to energy restriction as was shown in pair-fed control studies[41,43].

Most obese humans have increased serum leptin levels[14,15] and thus far the overall effect of leptin therapy on weight loss and metabolic parameters has been modest[44]. It is likely that very high plasma levels of the hormone are needed to overcome the leptin-resistant state. A final point directing to an antidiabetogenic effect of leptin is that both in lipodystrophic rodents[45] and humans (who have an extreme deficit of subcutaneous adipose tissue)[46], a condition associated with severe insulin resistance with hyperglycaemia, hyperinsulinaemia and hypertriglyceridaemia, leptin therapy corrects all these metabolic abnormalities, independent of the accompanying reduction in food intake.

Hypotheses with regard to the glucose and insulin lowering effect of leptin

As mentioned before, leptin seems to have an insulin-sensitising effect on the whole-body level but conflicting results were reported when individual tissues were examined. Most *in vitro* experiments suggest a diabetogenic effect of leptin[38]. Beside the differences between animals and humans, sources of leptin and time of exposure to this hormone might also play a causative role in the differences found. Furthermore, the fact that leptin exerts a glucose- and insulin-lowering effect and improves insulin sensitivity *in vivo*, suggests involvement of centrally acting mechanisms. This concept is further supported by the observation that leptin fails to reverse insulin resistance and lipid accumulation in mice with ventromedial hypothalamic lesions[47]. The peripheral mechanism by which leptin exerts its glucose- and insulin-lowering effect might be *via* promoting fatty acid oxidation and triglyceride synthesis. Indeed, leptin administration activates 5'-AMP-activated protein kinase (AMPK) in skeletal muscle, leading to the inhibition of acetyl coenzyme A carboxylase and subsequently stimulation of fatty acid oxidation. The resulting intramyocellular lipid depletion will enhance insulin sensitivity[48].

Apart from insulin-sensitising effects, leptin diminishes hyperinsulinaemia probably *via* inhibition of insulin secretion. Functional leptin receptors have been demonstrated on insulin secreting β-cells of the pancreas[49]. Leptin inhibits glucose-stimulated insulin secretion both *in vitro*[50] and *in vivo*[51]. The mechanism involved is activation of the ATP-sensitive potassium channels in the β-cell. Finally, leptin shares intracellular pathways with insulin, both in peripheral tissues and in the CNS[52]. Many effects of both insulin and leptin are mediated *via* activation of PI-3 (phosphatidylinositol-3-phosphate) kinase, so degree of cross talk between insulin and leptin may exist at the level of PI-3 kinase. Effects of leptin on insulin signalling have been studied and support an inhibitory effect of leptin on insulin signalling at the level of tyrosine phosphorylation of IRS-1 and PI3-kinase binding to IRS-1[38]. The effect of hyperinsulinaemia on intracellular leptin signalling has rarely been addressed but in one study supraphysiogical concentrations of insulin completely cancelled out the leptin-induced insulin response[53].

Conclusion

Thus, leptin is an adipocyte secretory product that is not only involved in food intake and energy metabolism but clearly also has a role in glucose metabolism. Since plasma leptin levels are positively correlated with BMI, obesity seems to reflect a leptin-resistant state. Resistance for the action of leptin could promote obesity *via* decreased energy expenditure and a failure to diminish food intake. Furthermore, since leptin has a glucose- and insulin-lowering effect on the whole-body level *in vivo*, resistance for this effect could induce insulin resistance. One explanation for the insulin resistance seen in obesity might be that the high leptin levels interfere with insulin signalling. Another possibility is that there is a diminished activation of AMPK due to impaired leptin signalling. The resultant decrease in fatty acid oxidation will lead to an increase in intramyocellular lipids and thus to insulin resistance. Finally, both peripheral and central leptin resistance must be involved in insulin-resistant states since leptin treatment fails to correct insulin resistance in mice with ventromedial hypothalamic lesions.

Resistin

Discovery, structure, genetic locus, sites and modulators of expression of resistin

Resistin is a unique protein with cysteine-rich residues[54], which belongs to a class of tissue-specific secreted proteins termed the RELM (resistin-like molecule)/FIZZ (found in inflammatory zone) family. Resistin/FIZZ 3 is specifically expressed and secreted by adipocytes. The gene encoding resistin in mice has been named *Retn*. The regulation of resistin gene expression is controversial, see Table 2.

Resistin in obesity and insulin resistance

The initial report by Steppan *et al.*[54] suggested that resistin might constitute the link between obesity and insulin resistance. Resistin serum levels were increased in obese mice and resistin gene expression was induced during adipocyte differentiation. In addition, administration of resistin impaired glucose tolerance and insulin action in wild-type mice and *in vitro* in 3T3-L1 adipocytes whereas resistin antibody improved insulin sensitivity. The fact that thiazolidine-

Table 2. Regulators of resistin expression.

Factor	Decreasing resistin	Increasing resistin	No effect
Thiazolidinediones	[54-56,58]	[59]	[60]
Insulin	[56,58]	[59,61]	
Glucose		[58]	
Dexamethasone		[56,58]	
β-adrenergic agonists	[62]		[56]
TNF-α	[58,63]		
Epinephrine	[58]		

Factors that have been reported to increase or decrease resistin expression with their references.

diones suppressed resistin secretion led to the hypothesis that these insulin-sensitisers exert their effect *via* downregulation of resistin gene expression. An increase in adipocyte gene expression during 3T3-L1 adipocyte differentiation[61] and after the induction of high-fat-diet induced obesity[57] was found in two other studies. Several other investigators, however, found a decreased resistin gene expression in WAT in different models of rodent obesity and insulin resistance[59,64,65], and resistin did not seem to be involved in the aetiology of insulin resistance in Fischer 344 rats, a good model for the metabolic syndrome in humans[66].

Studies in humans are even more controversial. One study could not detect any resistin mRNA in human fat cells at all in subjects with varying degrees of insulin resistance and obesity[67]. Another investigator found increased resistin mRNA in adipose tissue of obese humans, compared with lean controls, but decreased mRNA in freshly isolated human adipocytes[60]. In addition, resistin mRNA was undetectable in a severely insulin resistant subject. Janke *et al*. found an increased resistin gene expression in cultured human preadipocytes compared with mature adipocytes but again no relationship between resistin gene expression and either insulin resistance or body weight could be detected[68]. Although the higher resistin mRNA levels found in abdominal fat tissue compared with thigh, could explain the increased metabolic abnormalities in abdominal obesity, the fact that resistin mRNA expression is very similar in subcutaneous and omental adipose tissue suggests that it is unlikely that resistin is the link between (visceral) adiposity and insulin resistance[69].

Conclusion

The conclusion must be that many questions have to be resolved. Conflicting results have been reported with regard to the factors regulating resistin gene expression (Table 2). This is probably due to the difference between 3T3-L1 cell lines and *in vivo* models. Furthermore, the observed relation between resistin mRNA, serum resistin levels and insulin resistance in rodents cannot readily be extrapolated to humans. Murine resistin is only about 56% identical to human resistin at the amino acid level. Even in mouse models it is still unclear whether resistin plays a causal role in insulin resistance. Experiments in resistin knockout mice and in transgenic mice (which overexpress resistin) will be needed to solve this problem, but even then the relevance of resistin to human diabetes remains unclear, especially because some groups have found only minimal expression of the hormone in human fat[69]. Furthermore it would be interesting to know how resistin exerts its presumed insulin-antagonising effects and what its target organs are. For that purpose the resistin receptor would have to be found and downstream signalling pathways have to be unravelled.

Adiponectin

Discovery, sites of expression and stimuli leading to adiponectin production

Adiponectin is a recently identified[70,71] adipocyte-specific secretory protein of about 30 kDa that appears to be involved in the regulation of energy balance and insulin action and also seems to have anti-inflammatory and anti-atherogenic properties.

Adiponectin is the product of the adipose tissue most abundant gene transcript-1 (apM1), which is exclusively expressed in WAT and is located on chromosome 3q27. Adiponectin is specifically expressed during adipocyte differentiation and is not detectable in fibroblasts. The expression of adiponectin is stimulated by insulin[70,72], IGF-1[72] and the TZDs[73]. Corticosteroids[72], TNF-α[74] and β-adrenerg stimulation[75] inhibit adiponectin gene expression in 3T3-L1 adipocytes.

Serum and mRNA levels of adiponectin in obesity and insulin resistance

Serum adiponectin levels are decreased in humans with obesity[76,77] and type 2 diabetes[76,78] as well as in obese and insulin-resistant rodents[79]. In addition, adiponectin gene transcription is decreased in adipocytes from obese[71] and diabetic[80] humans and rodents[71,79]. Plasma adiponectin concentrations increase after weight reduction in obese diabetic and non-diabetic patients[78]. The degree of plasma hypoadiponectinemia was more closely related to the degree of hyperinsulinaemia and insulin resistance than to the degree of adiposity[76]. Low plasma adiponectin concentrations predicted a decrease in insulin sensitivity[81] and an increase of type 2 diabetes[82] in Pima Indians as well as in a German population[83]. In non-diabetics, plasma adiponectin levels are also positively correlated with insulin sensitivity[84]. A recent study confirmed that the relation between low adiponectin levels and insulin resistance is not determined by obesity since low plasma adiponectin levels at baseline did not predict future obesity[85]. Finally, the fact that the insulin-sensitising TZDs strongly increase plasma adiponectin[73,86] further supports a role of adiponectin in insulin sensitivity.

Theory with regard to the possible mechanism of action of adiponectin

Administration of recombinant adiponectin to normal, obese and diabetic rodents led to acute normalisation of serum glucose levels[79,87,88]. Both decreased gluconeogenesis of the liver[87] and an increased fatty acid oxidation in muscle[79,88] have been proposed as underlying mechanisms. Recently, Yamauchi underscored his previous hypothesis[89]. Administration of adiponectin led to an increase of glucose utilisation and fatty acid oxidation in cultured myocytes and in soleus muscle of mice *in vivo*. In hepatocytes AMPK was activated as well, leading to a reduction in gluconeogenesis.

In addition, it has been shown that administering only the globular domain of adiponectin instead of full-length adiponectin is much more effective in improving insulin sensitivity because this fragment augments insulin-induced phosphorylation of insulin receptor substrate

1 (IRS-1) and protein kinase B in skeletal muscle[79]. Thus, adiponectin might exert its insulin-sensitising effect *via* the following mechanisms: (i) increased fatty acid oxidation, leading to a lower muscle triglyceride content and lower plasma concentrations of free fatty acids which will both improve insulin signalling; (ii) direct improvement of insulin signalling; (iii) inhibition of gluconeogenesis, partly *via* reduced substrate delivery and partly *via* reduction of molecules involved in gluconeogenesis by activation of AMPK.

Disappointingly, no positive correlation between plasma adiponectin levels and 24-hour respiratory quotient (RQ) measurement (pointing to an increase in carbohydrate metabolism) could be demonstrated in healthy nondiabetic Pima Indians[90]. This does not rule out, however, that administration of adiponectin to subjects with low levels of this hormone will increase RQ and energy expenditure.

The acylation-stimulating protein (ASP)- pathway

ASP production and site of action

Acylation-stimulating protein (ASP) is a 76 amino acid protein identical to C3adesArg, a cleavage product of complement factor 3 (C3) formed *via* interaction of C3 with factor B and adipsin. C3, factor B and adipsin are all components of the alternative complement pathway and are produced by the adipocyte in a differentiation-dependent manner[91].

The major site of action of ASP appears to be on the adipocytes themselves, which have a specific saturable receptor for ASP[92]. In human adipocytes there are differentiation and site-specific differences in ASP binding which are proportional to the ASP response: differentiated adipocytes bind more ASP and have a greater response to ASP than undifferentiated adipocytes[93]. Furthermore, subcutaneous adipose tissue has greater affinity and greater specific binding to ASP than undifferentiated adipocytes[94].

ASP promotes triglyceride storage

ASP promotes triglyceride storage in adipocytes *via* three mechanisms. Firstly, ASP increases fatty acid esterification in adipocytes by increasing the activity of diacylglycerol acyltransferase, which is the final enzyme involved in triglyceride synthesis[91]. Secondly, ASP stimulates glucose transport in human and murine adipocytes and preadipocytes[93]. This effect on glucose transport is accomplished *via* translocation of cell-specific glucose transporters to the cell membrane. Thirdly, ASP decreases lipolysis *via* inhibition of hormone-sensitive lipase[95]. The effects of ASP are independently of and additional to the action of insulin[95].

Stimuli leading to ASP production

In vitro studies in cultured adipocytes indicate that insulin[96] and even more so chylomicrons[96,97] increase ASP production. *In vivo*, plasma ASP concentrations seem to show little change after an oral fat load[98]. There is, however, postprandially an increased venoarterial

gradient of ASP across a subcutaneous abdominal tissue bed with a maximum after 3 to 5 hours, indicating increased adipose tissue ASP production[98]. This increase in ASP postprandially is substantially later than the increase in insulin but shows a close temporal relationship with maximal plasma triacylglycerol clearance[98].

Plasma ASP levels in obesity

An excellent review on the physiology of ASP in humans and rodents has recently been published[99]. Plasma levels of ASP are 225-fold lower (weighted average 28.3 nM) than its precursor C3. Studies measuring plasma ASP levels should therefore be interpreted with caution while it might very well be that ASP acts as a paracrine hormone[99]. Plasma ASP levels are increased in obese humans[100-103] and are reduced after fasting or weight loss[101;103]. ASP has also been shown to be significantly increased in type 2 diabetes[102,104] but since type 2 diabetes is often associated with obesity this might be a confounding factor. On the other hand, plasma ASP levels were inversely correlated to glucose disposal during a euglycaemic clamp in humans[102]. Adipocytes from obese humans are as responsive to ASP as adipocytes from lean people[105]. Thus the increased levels of ASP in human obesity in the face of a similar responsiveness to ASP compared with lean subjects, may promote energy storage, leading to adiposity.

Relation between ASP-enhanced triglyceride clearance and insulin resistance

ASP production is increased in obese mice. Intraperitoneal (i.p.) administration of ASP to normal mice resulted in accelerated postprandial triglyceride (TG) and non-esterified fatty acid (NEFA) clearance after an oral fat load[106]. In addition, plasma glucose levels returned faster to basal levels. C3 knockout mice (KO), which are unable to produce ASP, showed delayed plasma triglyceride clearance after an oral fat load in the absence of any change in fasting plasma TG levels. Administration of exogenous ASP enhanced plasma TG clearance[107]. Remarkably, these C3 KO mice were more insulin sensitive, had a reduced fat mass and yet an increased food intake. It was later shown that the hyperphagia/leanness was balanced by an increase in energy expenditure[108].

Conclusion

In summary, ASP promotes storage of energy as fat. Decreased ASP production decreases lipid storage and induces an obesity-resistant state and improved insulin sensitivity. Plasma ASP levels are increased in obese humans; whether this is the effect or cause of the increased adipose tissue mass remains to be elucidated. *Post or propter*, increased ASP levels together with a continuing responsiveness of the ASP receptor will lead to further triglyceride storage. Although enhanced fatty acid trapping will decrease free fatty acid levels and hence diminish hepatic gluconeogenesis, increased ASP functioning in skeletal muscle will lead to an increase in skeletal muscle triglyceride storage leading to insulin resistance.

Tumour necrosis factor-α *(TNF*-α*)*

Structure of TNF-α, sites of production and receptor interaction

TNF-α is a cytokine produced mainly by activated macrophages in response to invasive stimuli, but also by non-immune cells such as muscle and adipose tissue. Furthermore, TNF-α has a variety of biological effects in various tissues and cell-types, and can thus be considered a multifunctional cytokine[109].

TNF-α is produced as a 26-kDa membrane-bound precursor that is proteolytically cleaved to a 17-kDa soluble form[109]. The cytokine interacts with two membrane-bound receptors, a 60-kD and an 80-kD subtype also called type I and type II receptor (TNFR1 and TNFR2). These receptors have different cellular and tissue distribution patterns and can bind other cytokines as well. TNF-α has a higher affinity for TNFR-1 than for TNFR-2[109]. Due to the high affinity for its receptor TNF-α can act either as an autocrine or paracrine cytokine at low concentrations or as an endocrine cytokine at high concentrations.

In addition to the membrane-bound receptors, soluble forms of the two receptors exist for which TNF-α has an even higher affinity. When TNF-α is bound to these soluble receptors no interaction can take place with the membrane-bound forms and thus TNF-α action is inhibited. Therefore, the physiological role of the soluble receptors may be to regulate TNF-α action.

Modulators of TNF-α production

In macrophages and monocytes, the expression and production of TNF-α is stimulated by endotoxins such as lipopolysacharide (LPS). LPS resulted in a fivefold stimulation of TNF-α in human adipose tissue and isolated adipocytes *in vitro,* the latter indicating that it is unlikely that the response is entirely due to macrophages and monocytes in the stromal vascular fraction of adipose tissue. Insulin and glucocorticoids did not have a significant effect on TNF-α release from human adipose tissue or isolated adipocytes *in vitro*[110]. Thiazolidinediones reduced adipocyte TNF-α release in obese rodents[111] but no effect was seen in human adipose tissue *in vitro*[110]. Since high-fat diets resulted in a significant increase in TNF-α mRNA and protein in epididymal and retroperitoneal fat pads in rats, free fatty acids and/or triglycerides may play an important role as inducers of TNF-α expression[112].

Effect of TNF-α on glucose and lipid metabolism

Firstly, TNF-α inhibits preadipocyte differentiation by downregulating the expression of two important adipocyte transcription factors: PPAR-γ and CEBP/α[113]. Secondly, TNF-α reduces the expression of GLUT-4, glycogen synthase and fatty acid synthase, which are essential for insulin-mediated glucose uptake and the subsequent conversion of glucose to glycogen or fatty acids. Furthermore, genes involved in the uptake of free fatty acids and the subsequent conversion to triglycerides, such as lipoprotein lipase, long-chain fatty acyl-CoA synthethase

and diacylglycerol acyltransferase, were also downregulated by TNF-α[113]. The above-mentioned changes in gene expression lead to a diminished insulin-stimulated glucose uptake and an altered lipid metabolism which can, *via* accumulation of triglycerides in various organ systems, eventually lead to insulin resistance of the muscle and liver.

In addition, insulin resistance can be induced *via* a direct toxic effect of TNF-α on intracellular insulin signalling[114]. TNF-α reduces the insulin-stimulated autophosphorylation of the insulin receptor in a variety of cell types. It does so by phosphorylation of serine residues at the insulin receptor substrate-1 (IRS-1); this modified IRS-1 subsequently interferes with the insulin signalling capacity of the insulin receptor[114].

Relation between TNF-α, obesity and insulin resistance

A positive relationship between obesity, insulin resistance and adipose tissue mRNA levels of TNF-α has clearly been established in rodent models[115]. Furthermore, mice with no functional copy of the TNF-α gene (TNF-α $^{-/-}$) although developing marked obesity on a high-fat, high-energy diet, remained highly insulin sensitive as compared to their control litter mates (TNF-α $^{+/+}$)[116].

In contrast to rodents, the role of TNF-α in the induction of insulin resistance in humans is less clear. Although there seems to be a positive relationship between obesity and TNF-α mRNA and protein levels in adipose tissue in humans *in vitro*[117-119], TNF-α is expressed at much lower levels in humans as compared to rodents[117-119]. In addition, no difference in TNF-α concentration was found in a vein draining subcutaneous adipose tissue as compared to a peripheral vein, suggesting no or very low TNF-α production *in vivo*[120]. Furthermore, circulating TNF-α concentrations in obese diabetic and non-diabetic patients are not substantially elevated[118,120]. With regard to a direct relationship between TNF-α and insulin sensitivity *in vivo*, two studies found a strong and positive correlation between adipose tissue mRNA levels and hyperinsulinaemia[117,118]. When the relation between adipose tissue TNF-α secretion and insulin-stimulated glucose transport was examined, a strong inverse relationship was found that was independent of fat cell volume, age and BMI[122].

However, other studies[121,123] showed no significant relationship between adipose tissue mRNA for TNF-α and insulin sensitivity. Furthermore, treatment of insulin-resistant subjects with anti-TNF-α antibodies did not improve insulin sensitivity[124]. All these results implicate that TNF-α might have an effect on insulin resistance but that it must be a local factor. Interestingly, TNF-α is also produced by muscle, and muscle TNF-α production is increased in obesity[125]. Since adipose tissue dispersed within muscle is correlated with insulin resistance, the effect of fat cell secretory products on insulin signalling in skeletal muscle cells was recently studied in a model in which muscle cells were co-cultured with adipocytes. A disturbance of insulin signalling was found, but TNF-α did not seem to be involved[126].

Conclusion

In conclusion, TNF-α is a multifunctional cytokine produced by adipocytes in proportion to the percentage body fat. TNF-α has a variety of metabolic effects, including increased lipolysis, decreased lipogenesis and decreased insulin-stimulated glucose transport, contributing to insulin resistance. These effects are induced by modulation of genes involved in glucose and lipid metabolism. Furthermore, TNF-α directly interferes with early steps of insulin signalling. However, the role of TNF-α in obesity-induced insulin resistance in humans is not quite clear yet, as might be obvious from the contradicting results mentioned in the previous paragraph. The low plasma levels of TNF-α in humans indicate that the hormone most likely acts in a paracrine and/or autocrine manner. This might be the reason why treatment with anti-TNF-α did not improve insulin sensitivity in humans *in vivo*.

Interleukin-6 (IL-6)

Structure, genetic locus and site of production of IL-6

IL-6 is a circulating, multifunctional cytokine that is produced by a variety of cell types including fibroblasts, endothelial cells, monocytes/macrophages, T-cell lines, various tumour cell lines and adipocytes. The protein has a molecular mass of 21 to 28 kDa, depending on the cellular source and preparation. The gene encoding IL-6 is localised on chromosome 7p21 in humans[127].

Although human adipocytes do produce IL-6, adipocytes accounted for only 10% of total adipose tissue when IL-6 production by isolated adipocytes prepared from omental and subcutaneous fat depots was examined[128]. This means that cells in the stromal vascular fraction of adipose tissue have a major contribution in adipose tissue IL-6 release. The concentrations of IL-6 in adipose tissue are up to 75 ng/mL, which is well within the range to elicit biological effects[129]. Furthermore, plasma levels of IL-6 are markedly elevated in obesity and up to 30% of plasma levels could be derived from adipocytes[130].

Modulators of IL-6 production

The stimuli leading to IL-6 production differ with the cell type; here only IL-6 production by adipocytes will be discussed. Both in rodent and human adipocytes, IL-6 production is stimulated by catecholamines and inhibited by glucocorticoids, whereas insulin has no effect whatsoever[128,131,132]. Finally, another stimulator of IL-6 release is TNF-α, which has been reported to produce a 30-fold [113] increase in IL-6 production in 3T3-L1 adipocytes. Interestingly, IL-6 in turn inhibits the release of TNF-α!

IL-6 acts via receptor interaction

IL-6 acts through binding at and activation of a specific receptor, belonging to the class I cytokine receptors, which act through JAK-STAT signalling (see Fig. 3 where leptin signalling

is explained)[133]. The IL-6 receptor consists of two membrane glycoproteins, a 80-kDa ligand binding component and a 130-kDa signal-transducing component (gp130). The 80-kDa component binds IL-6 with low affinity; this complex subsequently binds with high affinity to gp130 after which signal transduction can take place[127].

Soluble forms of the IL-6 receptor have been found but neither their functional significance nor the regulation of their production is understood.

Metabolic effects of IL-6

IL-6 has pleiotropic effects on various cell types. Here, we will only focus on its role in glucose and lipid metabolism. Infusion of rhIL-6 to humans increased whole-body glucose disposal and glucose oxidation but increased hepatic glucose production[134] and the fasting blood glucose concentration in a dose-dependent manner[135]. With regard to lipid metabolism, IL-6 decreases adipose tissue lipoprotein lipase (LPL) activity[129] and has been implicated in the fat depletion taking place during wasting disorders, such as cancer, perhaps *via* an increase in plasma norepinephrine, cortisol, resting energy expenditure and fatty acid oxidation as was assessed in eight renal cancer patients[134]. In rats, IL-6 increased hepatic triglyceride secretion partly because the increase of adipose tissue lipolysis resulted in an increased delivery of free fatty acids to the liver[136]. This increased release of free fatty acids following rhIL-6 infusion was observed in humans as well[134].

IL-6 in obesity and insulin resistance

In both mice [132]and humans, IL-6 mRNA in adipose tissue[137,138] but even more so plasma levels of IL-6 are positively correlated with BMI[132,137,138]. Weight loss is associated with a reduction in serum and IL-6 mRNA levels. After one year of a multidisciplinary programme of weight reduction, obese women lost at least 10% of their original weight and this was associated with a reduction of basal serum IL-6 levels from 3.18 to 1.7 pg/mL ($p<0.01$)[138]. In another study, both IL-6 mRNA in adipose tissue and IL-6 serum levels were reduced with weight loss after three weeks of a very low calorie diet in obese women[138]. In this study, insulin sensitivity as assessed by the fasting insulin resistance index (FIRI= fasting glucose x fasting insulin/25) improved as well. The reduction in IL-6 levels could play a role in this improvement, since several studies found a significant correlation between circulating IL-6 levels and insulin sensitivity measured by either an intravenous glucose tolerance test[137] or the fasting insulin resistance index[138]. Recently this correlation between circulating IL-6 and insulin sensitivity was confirmed using the "gold standard for insulin sensitivity": the hyperinsulinaemic euglycaemic clamp[140]. In addition, a high correlation between adipose tissue IL-6 content and insulin sensitivity was found, both *in vivo* and *in vitro*. Furthermore, for the first time IL-6 receptors were demonstrated in 60% of the subcutaneous adipocytes suggesting that IL-6 can alter adipocyte metabolism *via* autocrine or paracrine mechanisms and have a local influence on insulin sensitivity[140]. Further support for a relationship between IL-6 and insulin sensitivity

comes from a genetic study. It appeared that subjects with an IL-6 gene polymorphism had lower IL-6 levels, a lower area under the glucose curve after an oral glucose tolerance test, lower glycosylated haemoglobin (HbA_{1c}) and fasting serum insulin levels and an increased insulin sensitivity index as compared with carriers of the normal IL-6 allele, despite similar age and BMI[141]. Finally, basal serum IL-6 levels are higher in type-2-diabetic patients[142].

In contradiction with the abovementioned positive correlation of IL-6 with BMI and inverse relation with insulin sensitivity is the observation that the lack of IL-6 also leads to obesity and a disturbed glucose tolerance, at least in mice.

Conclusion

Various studies show a clear relationship between increased IL-6 levels and obesity[132,137,138], and between IL-6 levels and insulin resistance[137,138,140] even when corrected for BMI[137]. Furthermore, basal plasma IL-6 levels are higher in patients with type 2 diabetes[142] and subjects with an IL-6 gene polymorphism clearly have lower serum IL-6 levels and this is correlated with improved insulin sensitivity and postload glucose levels[141]. IL-6 does have different effects on the various end-organ tissues, however, with on the one hand improved glucose uptake in adipocytes and whole-body glucose disposal, and on the other hand an increased hepatic glucose output, decreased LPL activity (leading to decreased triglyceride clearance) and increased hepatic triglyceride synthesis. How then does IL-6 fit in the insulin resistance syndrome? Is there a causal effect or are the increased IL-6 levels found in obesity and insulin resistance merely a reflection of the pathogenetic state or the increased adipose tissue mass? Is IL-6 detrimental to health or does it have a positive role in health. If we start from the principle that IL-6 production is increased in obesity and that it is involved in inducing insulin resistance, what would be the mechanisms by which IL-6 causes insulin resistance? Firstly, it has to be noted that omental fat produces threefold more IL-6 than subcutaneous adipose tissue[128]. Because venous drainage of omental tissue flows directly to the liver and IL-6 is known to increase hepatic triglyceride secretion[134,136] this might explain the hypertriglyceridaemia associated with visceral obesity. As mentioned before, increased triglyceride content of muscle and liver leads to insulin resistance. Secondly, IL-6 signal transduction is mediated *via* JAK-STAT signalling; it is possible that feedback mechanisms interfering with insulin signalling exist. Thirdly, IL-6 has opposing effects to those of insulin on hepatic glycogen metabolism[143] and increases hepatic glucose production[135]. On the contrary, despite an increase of IL-6 in obesity, insulin resistance and type 2 diabetes, there is evidence that IL-6 improves insulin sensitivity; (i) IL-6 increases glucose uptake in 3T3-L1 adipocytes[144]; (ii) infusion of rhIL-6 to humans increased whole-body glucose disposal and glucose oxidation[134]; (iii) IL-6 inhibits TNF-α production, a cytokine with deleterious effects on insulin sensitivity; and (iv) physical exercise, which is related to an improvement in insulin sensitivity, is coupled with an increased IL-6 secretion[145]. It might be that muscle-derived IL-6 downregulates TNF-α[145].

So, in conclusion, it is still not clear whether IL-6 has a positive or a negative metabolic role in health. One of the reasons of the contradicting results might be that there is a difference in the acute and chronic exposure to IL-6 with regard to health implications. Furthermore, local and CNS-acting effects of IL-6 might be different. More transgenic mice studies can help shed light on the role of IL-6 in insulin resistance. Up until now, it is quite possible that the increased IL-6 levels observed in adiposity and type 2 diabetes are the cause of an increased production by the enlarged adipose tissue mass and/or an attempt to overcome either insulin resistance or another metabolic effect, for example IL-6 resistance.

DISCUSSION

Obesity, defined as a BMI > 30 kg/m^2, is the consequence of a chronic imbalance between energy intake and energy expenditure. This is partly due to modern society with excess ('fast') food intake and a sedentary life style. The role that should be ascribed to primary defects in energy storage caused by adipocyte secretory products or impaired hypothalamic functioning remains to be elucidated. At the moment a combination of the two seems the most likely. It is well known that obesity is associated with insulin resistance and type 2 diabetes mellitus. An overwhelming amount of evidence indicates that visceral fat is associated with glucose intolerance and insulin resistance[146-151], along with other facets of the metabolic syndrome such as dyslipidaemia. Therefore, in the past, the predominant theory used to explain the link between obesity and insulin resistance was the portal/visceral hypothesis[152], which states that increased visceral adiposity leads to an increased free fatty acid flux into the portal system and inhibition of insulin action *via* Randle's effect[153]. However, several investigators have challenged the singular importance of visceral adiposity in inducing insulin resistance. They found an independent association between total fat mass and subcutaneous truncal fat mass and insulin resistance[154-156]. Furthermore, the observations that (i) triglyceride content within skeletal muscle cells is increased in obesity[157] and type 2 diabetes mellitus[157,158] and is a strong predictor of insulin resistance[159]; and (ii) lipodystrophy is associated with insulin resistance as well[160,161], necessitated the need to develop new theories to explain the link between adipose tissue and insulin resistance[162]. A well-accepted theory is that of ectopic fat storage[162,163]. A limitation in the capacity of adipose tissue to store triglycerides would divert triglycerides to be deposited in liver cells and skeletal muscle cells[162,163]. The cause of the ectopic fat storage is unclear. It might be due to impaired fat oxidation[162], since inhibition of fat oxidation in rodents increased intracellular lipid content and decreased insulin action[164]. Furthermore, a mutation in the AGPAT2 gene encoding 1-acylglycerol-3-phosphate O-acyltransferase inhibits triacylglycerol synthesis and storage in adipocytes but not in hepatocytes, thus leading to hepatosteatosis, because the latter can accumulate triacylglycerol *via* AGPAT-1[165]. Another possibility is the central and/or peripheral action of leptin, since leptin therapy has been as-

sociated with the reversal of insulin resistance and hepatic steatosis in patients with lipodystrophy[46] and also with improvement of intramyocellular lipid content[163]. Finally, a defect in the proliferation and/or differentiation of adipocytes, whether or not due to alterations in the expression of transcription factors[166] can lead either to impaired adipocyte triglyceride storage and/or adipocyte hypertrophy. This is where the third hypothesis emerges: the adipocyte as an endocrine organ[162]. Adipocytes secrete a large number of cytokines and hormones that act in a paracrine, autocrine and endocrine manner on adipocyte- and whole-body metabolism. It is plausible that these enlarged adipocytes are deregulated in their transcriptional setting and secrete a different pattern of hormones or different amounts of them compared with small adipocytes. On the other hand, enlarged adipocytes might merely be a manifestation of other, yet to be defined, pathogenetic factors[162].

In obese humans and rodents there is, besides numerous other proteins and cytokines that have not been discussed here, overproduction of leptin[14,15], IL-6[132,137,138], TNF-α[115,117-119], ASP[100,101] and resistin[54,60], and a decreased production of adiponectin[71,77,78,80] (see Fig. 5). Of leptin[23], TNF[74] and IL-6[127] it is known that they act *via* receptors on the cell surface and subsequent intracellular signalling cascades. As can be seen in Fig. 5, all three adipocytokines decrease food intake and increase energy expenditure and lipolysis together with a decrease in lipogenesis. These are well-adaptive mechanisms to prevent further weight gain. Since all these adipocytokines are increased in adiposity it is unlikely that they are the cause of adiposity unless there is an impairment in (adipo)cytokine signalling. Interestingly, leptin and TNF-α have opposing effects with regard to insulin sensitivity. TNF-α interferes with insulin signalling and downregulates many genes encoding for proteins involved in glucose and free fatty



Figure 5.

Hyperplasia and hypertrophy of adipocytes, as seen in adiposity, leads to an increased production of leptin, TNF-α, IL-6, resistin, ASP and many other proteins, and a decreased production of adiponectin. The results of these increases, respectively decrease, are mentioned below each protein.

acid uptake[113]. Leptin can act through some components of the insulin-signalling cascade as well[52]. The relation between TNF-α and leptin in humans is not clear. Infusion of TNF-α to patients has been reported to acutely raise serum leptin levels[167], whereas chronic exposure of cultured human adipocytes to TNF-α resulted in a decrease in leptin production[168]. If TNF-α increases leptin production this might be an adaptive mechanism to compensate for the TNF-α induced impaired insulin signalling.

When we take a further look at the mutual coherence of the adipocyte secretory factors it is striking that both insulin and TNF-α are, somehow, involved in the regulation of all of the adipocyte secretory products. Insulin increases the production of leptin[19,20,36,37], adiponectin[70,72] and ASP[96], whereas no effect has been recorded with regard to TNF-α[110] and a potentially positive effect on resistin levels[61]. TNF-α downregulates resistin[58] and stimulates the production of leptin[169], adiponectin[74] and IL-6[113]. The problem is that some of these factors lead to an improvement of insulin sensitivity, whereas others have just the opposite effect. This makes it extremely difficult to elucidate which factors are most important in regulating insulin sensitivity. Furthermore, the time of exposure to a stimulus seems to be important. Thus it seems that leptin and insulin are long-term regulators with regard to food intake and energy expenditure, whereas insulin has a direct effect on glucose uptake and lipolysis.

How do these adipocyte-derived factors mediate their effects? What they all seem to have in common is a change in the expression of genes encoding for proteins involved in glucose and lipid metabolism. Transcription of genes can only take place if they are activated, which always occurs *via* some kind of ligand-receptor interaction followed by an intracellular signal transduction. Cytokine signalling proceeds in part *via* the JAK-STAT pathway[170]. The actions of leptin, TNF-α and IL-6 may influence each other *via* common signalling steps. Furthermore, it is known that leptin can signal through some components of the insulin-signalling cascade such as IRS-1 and -2, PI3K and MAPK and can modify insulin-induced changes in gene expression *in vitro* and *in vivo*[171]. TNF-α can interfere with the early steps of insulin signalling as well[114]. So, more and more evidence exists that the adipocyte secretory products leptin, IL-6 and TNF-α not only interact with each other but also with insulin on the level of intracellular signal transduction.

In the case of obesity and hyperinsulinaemia there is an increase in hormones and cytokines produced by the adipose tissue. These hormones subsequently mediate a change in the expression of genes encoding for proteins involved in glucose and lipid metabolism. In case of ASP these changes promote triglyceride uptake. However, in case of leptin, IL-6, TNF-α and adiponectin there is a deleterious effect on glucose uptake and fatty acid oxidation leading to insulin resistance. The effect of increased serum resistin levels remains to be elucidated. Everything seems to come down to interference with intracellular signal transduction, not only of insulin but also of the various adipocyte secretory products, with a subsequent change in the expression of genes involved in glucose and lipid metabolism leading to a diminished glucose uptake and fatty acid oxidation. The latter will, *via* accumulation of tri-

glycerides in liver cells and muscle cells, enhance insulin resistance, thus further impairing glucose uptake.

CONCLUDING REMARKS

It is now well established that adipose tissue not only has an important function in the storage and release of triglycerides but also has an important effect on whole-body metabolism and energy homeostasis *via* the production of various hormones and cytokines.

Adipose tissue not only responds to insulin, glucagon, cortisol and catecholamines but also to cytokines and products that it produces itself, thereby regulating its own metabolism and cell size. Some of the products produced by the adipocytes, such as TNF-α and leptin, are clearly involved in the induction of insulin resistance. The role of others (resistin, IL-6) has yet to be defined. Their increase in obesity is at least a manifestation of the increased adipose tissue mass itself. Further research is needed to come to a better understanding of the molecular pathways regulating the production of these hormones, their individual actions and target organs, and finally their mutual interaction and role in insulin resistance. These new insights provide the basis for the development of improved therapies for obesity and insulin resistance-related diseases as type 2 diabetes and cardiovascular complications.

REFERENCES

1. Matthaei S, Stumvoll M, Kellerer M, Haring HU. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 2000; 21(6):585-618.
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21(9):1414-1431.
3. Bloomgarden ZT. American Diabetes Association Annual Meeting, 1999: diabetes and obesity. Diabetes Care 2000; 23(1):118-124.
4. Gregoire FM, Smas CM, Sul HS. Understanding adipocyte differentiation. Physiol Rev 1998; 78(3):783-809.
5. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM. Transcriptional regulation of adipogenesis. Genes Dev 2000; 14(11):1293-1307.
6. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996; 1302(2):93-109.
7. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20(5):649-688.
8. Kim JB, Wright HM, Wright M, Spiegelman BM. ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc Natl Acad Sci U S A 1998; 95(8):4333-4337.
9. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997; 89(3):331-340.
10. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional loning of the mouse obese gene and its human homologue. Nature 1994; 372(6505):425-432.
11. Ahima RS, Flier JS. Leptin. Annu Rev Physiol 2000; 62:413-437.
12. Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med 1999; 130(8):671-680.
13. Wauters M, Considine RV, Gaal LF van. Human leptin: from an adipocyte hormone to an endocrine mediator. Eur J Endocrinol 2000; 143(3):293-311.
14. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334(5):292-295.
15. Lonnqvist F, Arner P, Nordfors L, Schalling M. Overexpression of the obese (ob) gene in adipose tissue of human obese subjects. Nat Med 1995; 1(9):950-953.
16. Boden G, Chen X, Mozzoli M, Ryan I. Effect of fasting on serum leptin in normal human subjects. J Clin Endocrinol Metab 1996; 81(9):3419-3423.
17. Schoeller DA, Cella LK, Sinha MK, Caro JF. Entrainment of the diurnal rhythm of plasma leptin to meal timing. J Clin Invest 1997; 100(7):1882-1887.
18. Sinha MK, Ohannesian JP, Heiman ML, Kriauciunas A, Stephens TW, Magosin S et al. Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. J Clin Invest 1996; 97(5):1344-1347.
19. Kolaczynski JW, Nyce MR, Considine RV, Boden G, Nolan JJ, Henry R et al. Acute and chronic effects of insulin on leptin production in humans: Studies in vivo and in vitro. Diabetes 1996; 45(5):699-701.

20. Boden G, Chen X, Kolaczynski JW, Polansky M. Effects of prolonged hyperinsulinemia on serum leptin in normal human subjects. J Clin Invest 1997; 100(5):1107-1113.

21. Vos P de, Lefebvre AM, Miller SG, Guerre-Millo M, Wong K, Saladin R et al. Thiazolidinediones repress ob gene expression in rodents *via* activation of peroxisome proliferator-activated receptor gamma. J Clin Invest 1996; 98(4):1004-1009.

22. Miller SG, Vos P de, Guerre-Millo M, Wong K, Hermann T, Staels B et al. The adipocyte specific transcription factor C/EBPalpha modulates human ob gene expression. Proc Natl Acad Sci U S A 1996; 93(11):5507-5511.

23. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995; 83(7):1263-1271.

24. Schwartz MW, Seeley RJ, Campfield LA, Burn P, Baskin DG. Identification of targets of leptin action in rat hypothalamus. J Clin Invest 1996; 98(5):1101-1106.

25. Elmquist JK, Ahima RS, Elias CF, Flier JS, Saper CB. Leptin activates distinct projections from the dorsomedial and ventromedial hypothalamic nuclei. Proc Natl Acad Sci U S A 1998; 95(2):741-746.

26. Schwartz MW, Woods SC, Porte D, Jr., Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000; 404(6778):661-671.

27. Elmquist JK, Elias CF, Saper CB. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron 1999; 22(2):221-232.

28. Dijk G van. The role of leptin in the regulation of energy balance and adiposity. J Neuroendocrinol 2001; 13(10):913-921.

29. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995; 269(5223):546-549.

30. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995; 269(5223):543-546.

31. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395(6704):763-770.

32. Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH et al. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 1996; 348(9021):159-161.

33. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387(6636):903-908.

34. Strobel A, Issad T, Camoin L, Ozata M, Strosberg AD. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet 1998; 18(3):213-215.

35. Ryan AS, Elahi D. The effects of acute hyperglycemia and hyperinsulinemia on plasma leptin levels: its relationships with body fat, visceral adiposity, and age in women. J Clin Endocrinol Metab 1996; 81(12):4433-4438.

36. Widjaja A, Stratton IM, Horn R, Holman RR, Turner R, Brabant G. UKPDS 20: plasma leptin, obesity, and plasma insulin in type 2 diabetic subjects. J Clin Endocrinol Metab 1997; 82(2):654-657.

37. Nagasaka S, Ishikawa S, Nakamura T, Kawakami A, Rokkaku K, Hayashi H et al. Association of endogenous insulin secretion and mode of therapy with body fat and serum leptin levels in diabetic subjects. Metabolism 1998; 47(11):1391-1396.

38. Ceddia RB, Koistinen HA, Zierath JR, Sweeney G. Analysis of paradoxical observations on the association between leptin and insulin resistance. FASEB J 2002; 16(10):1163-1176.

39. Sivitz WI, Walsh SA, Morgan DA, Thomas MJ, Haynes WG. Effects of leptin on insulin sensitivity in normal rats. Endocrinology 1997; 138(8):3395-3401.

40. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995; 269(5223):540-543.

41. Chinookoswong N, Wang JL, Shi ZQ. Leptin restores euglycemia and normalizes glucose turnover in insulin- deficient diabetes in the rat. Diabetes 1999; 48(7):1487-1492.

42. Yaspelkis BB, III, Davis JR, Saberi M, Smith TL, Jazayeri R, Singh M et al. Leptin administration improves skeletal muscle insulin responsiveness in diet-induced insulin-resistant rats. Am J Physiol Endocrinol Metab 2001; 280(1):E130-E142.

43. Schwartz MW, Baskin DG, Bukowski TR, Kuijper JL, Foster D, Lasser G et al. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes 1996; 45(4):531-535.

44. Hukshorn CJ, van Dielen FM, Buurman WA, Westerterp-Plantenga MS, Campfield LA, Saris WH. The effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects. Int J Obes Relat Metab Disord 2002; 26(4):504-509.

45. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999; 401(6748):73-76.

46. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002; 346(8):570-578.

47. Chlouverakis C, Bernardis LL, Hojnicki D. Ventromedial hypothalamic lesions in obese-hyperglycaemic mice (obob). Diabetologia 1973; 9(5):391-395.

48. Greco AV, Mingrone G, Giancaterini A, Manco M, Morroni M, Cinti S et al. Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes 2002; 51(1):144-151.

49. Kieffer TJ, Heller RS, Habener JF. Leptin receptors expressed on pancreatic beta-cells. Biochem Biophys Res Commun 1996; 224(2):522-527.

50. Fehmann HC, Peiser C, Bode HP, Stamm M, Staats P, Hedetoft C et al. Leptin: a potent inhibitor of insulin secretion. Peptides 1997; 18(8):1267-1273.

51. Cases JA, Gabriely I, Ma XH, Yang XM, Michaeli T, Fleischer N et al. Physiological increase in plasma leptin markedly inhibits insulin secretion in vivo. Diabetes 2001; 50(2):348-352.

52. Sweeney G. Leptin signalling. Cell Signal 2002; 14(8):655-663.

53. Kellerer M, Lammers R, Fritsche A, Strack V, Machicao F, Borboni P et al. Insulin inhibits leptin receptor signalling in HEK293 cells at the level of janus kinase-2: a potential mechanism for hyperinsulinaemia- associated leptin resistance. Diabetologia 2001; 44(9):1125-1132.

54. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM et al. The hormone resistin links obesity to diabetes. Nature 2001; 409(6818):307-312.

55. Moore GB, Chapman H, Holder JC, Lister CA, Piercy V, Smith SA et al. Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice. Biochem Biophys Res Commun 2001; 286(4):735-741.

56. Haugen F, Jorgensen A, Drevon CA, Trayhurn P. Inhibition by insulin of resistin gene expression in 3T3-L1 adipocytes. FEBS Lett 2001; 507(1):105-108.

57. Li J, Yu X, Pan W, Unger RH. Gene expression profile of rat adipose tissue at the onset of high-fat-diet obesity. Am J Physiol Endocrinol Metab 2002; 282(6):E1334-E1341.

58. Shojima N, Sakoda H, Ogihara T, Fujishiro M, Katagiri H, Anai M et al. Humoral regulation of resistin expression in 3T3-L1 and mouse adipose cells. Diabetes 2002; 51(6):1737-1744.

59. Way JM, Gorgun CZ, Tong Q, Uysal KT, Brown KK, Harrington WW et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2001; 276(28):25651-25653.

60. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV et al. Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001; 50(10):2199-2202.

61. Kim KH, Lee K, Moon YS, Sul HS. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 2001; 276(14):11252-11256.

62. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Tumor necrosis factor alpha is a negative regulator of resistin gene expression and secretion in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2001; 288(4):1027-1031.

63. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Isoproterenol inhibits resistin gene expression through a G(S)-protein- coupled pathway in 3T3-L1 adipocytes. FEBS Lett 2001; 500(1-2):60-63.

64. Le Lay S, Boucher J, Rey A, Castan-Laurell I, Krief S, Ferre P et al. Decreased resistin expression in mice with different sensitivities to a high-fat diet. Biochem Biophys Res Commun 2001; 289(2):564-567.

65. Juan CC, Au LC, Fang VS, Kang SF, Ko YH, Kuo SF et al. Suppressed gene expression of adipocyte resistin in an insulin- resistant rat model probably by elevated free fatty acids. Biochem Biophys Res Commun 2001; 289(5):1328-1333.

66. Levy JR, Davenport B, Clore JN, Stevens W. Lipid metabolism and resistin gene expression in insulin-resistant Fischer 344 rats. Am J Physiol Endocrinol Metab 2002; 282(3):E626-E633.

67. Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001; 285(2):561-564.

68. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Resistin gene expression in human adipocytes is not related to insulin resistance. Obes Res 2002; 10(1):1-5.

69. McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S. Resistin, central obesity, and type 2 diabetes. Lancet 2002; 359(9300):46-47.

70. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270(45):26746-26749.

71. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996; 271(18):10697-10703.

72. Halleux CM, Takahashi M, Delporte ML, Detry R, Funahashi T, Matsuzawa Y et al. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun 2001; 288(5):1102-1107.

73. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y et al. Synthetic Peroxisome Proliferator-Activated Receptor-gamma Agonist, Rosiglitazone, Increases Plasma Levels of Adiponectin in Type 2 Diabetic Patients. Diabetes Care 2002; 25(2):376-380.

74. Kappes A, Loffler G. Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factor-alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. Horm Metab Res 2000; 32(11-12):548-554.

75. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Adiponectin gene expression is inhibited by beta-adrenergic stimulation *via* protein kinase A in 3T3-L1 adipocytes. FEBS Lett 2001; 507(2):142-146.

76. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86(5):1930-1935.

77. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257(1):79-83.

78. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20(6):1595-1599.

79. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7(8):941-946.

80. Statnick MA, Beavers LS, Conner LJ, Corominola H, Johnson D, Hammond CD et al. Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diabetes Res 2000; 1(2):81-88.

81. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002; 51(6):1884-1888.

82. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360(9326):57-58.

83. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361(9353):226-228.

84. Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003; 52(2):239-243.

85. Vozarova B, Stefan N, Lindsay RS, Krakoff J, Knowler WC, Funahashi T et al. Low plasma adiponectin concentrations do not predict weight gain in humans. Diabetes 2002; 51(10):2964-2967.

86. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50(9):2094-2099.

87. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7(8):947-953.

88. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 2001; 98(4):2005-2010.

89. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8(11):1288-1295.

90. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Ravussin E, Weyer C et al. Plasma adiponectin levels are not associated with fat oxidation in humans. Obes Res 2002; 10(10):1016-1020.

91. Cianflone K, Roncari DA, Maslowska M, Baldo A, Forden J, Sniderman AD. Adipsin/acylation stimulating protein system in human adipocytes: regulation of triacylglycerol synthesis. Biochemistry 1994; 33(32):9489-9495.

92. Saleh J, Christou N, Cianflone K. Regional specificity of ASP binding in human adipose tissue. Am J Physiol 1999; 276(5 Pt 1):E815-E821.

93. Murray I, Parker RA, Kirchgessner TG, Tran J, Zhang ZJ, Westerlund J et al. Functional bioactive recombinant acylation stimulating protein is distinct from C3a anaphylatoxin. J Lipid Res 1997; 38(12):2492-2501.

94. Maslowska MH, Sniderman AD, MacLean LD, Cianflone K. Regional differences in triacylglycerol synthesis in adipose tissue and in cultured preadipocytes. J Lipid Res 1993; 34(2):219-228.

95. Harmelen V van, Reynisdottir S, Cianflone K, Degerman E, Hoffstedt J, Nilsell K et al. Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin. J Biol Chem 1999; 274(26):18243-18251.

96. Maslowska M, Scantlebury T, Germinario R, Cianflone K. Acute in vitro production of acylation stimulating protein in differentiated human adipocytes. J Lipid Res 1997; 38(1):1-11.

97. Scantlebury T, Maslowska M, Cianflone K. Chylomicron-specific enhancement of acylation stimulating protein and precursor protein C3 production in differentiated human adipocytes. J Biol Chem 1998; 273(33):20903-20909.

98. Saleh J, Summers LK, Cianflone K, Fielding BA, Sniderman AD, Frayn KN. Coordinated release of acylation stimulating protein (ASP) and triacylglycerol clearance by human adipose tissue in vivo in the postprandial period. J Lipid Res 1998; 39(4):884-891.

99. Cianflone K, Xia Z, Chen LY. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta 2003; 1609(2):127-143.

100. Weyer C, Pratley RE. Fasting and postprandial plasma concentrations of acylation-stimulation protein (ASP) in lean and obese Pima Indians compared to Caucasians. Obes Res 1999; 7(5):444-452.

101. Sniderman AD, Cianflone KM, Eckel RH. Levels of acylation stimulating protein in obese women before and after moderate weight loss. Int J Obes 1991; 15(5):333-336.

102. Koistinen HA, Vidal H, Karonen SL, Dusserre E, Vallier P, Koivisto VA et al. Plasma acylation stimulating protein concentration and subcutaneous adipose tissue C3 mRNA expression in nondiabetic and type 2 diabetic men. Arterioscler Thromb Vasc Biol 2001; 21(6):1034-1039.

103. Cianflone K, Kalant D, Marliss EB, Gougeon R, Sniderman AD. Response of plasma ASP to a prolonged fast. Int J Obes Relat Metab Disord 1995; 19(9):604-609.

104. Ozata M, Gungor D, Turan M, Ozisik G, Bingol N, Ozgurtas T et al. Improved glycemic control increases fasting plasma acylation- stimulating protein and decreases leptin concentrations in type II diabetic subjects. J Clin Endocrinol Metab 2001; 86(8):3659-3664.

105. Walsh MJ, Sniderman AD, Cianflone K, Vu H, Rodriguez MA, Forse RA. The effect of ASP on the adipocyte of the morbidly obese. J Surg Res 1989; 46(5):470-473.

106. Murray I, Sniderman AD, Cianflone K. Enhanced triglyceride clearance with intraperitoneal human acylation stimulating protein in C57BL/6 mice. Am J Physiol 1999; 277(3 Pt 1):E474-E480.

107. Murray I, Sniderman AD, Cianflone K. Mice lacking acylation stimulating protein (ASP) have delayed postprandial triglyceride clearance. J Lipid Res 1999; 40(9):1671-1676.

108. Xia Z, Sniderman AD, Cianflone K. Acylation-stimulating protein (ASP) deficiency induces obesity resistance and increased energy expenditure in ob/ob mice. J Biol Chem 2002; 277(48):45874-45879.

109. Hube F, Hauner H. The role of TNF-alpha in human adipose tissue: prevention of weight gain at the expense of insulin resistance? Horm Metab Res 1999; 31(12):626-631.

110. Sewter CP, Digby JE, Blows F, Prins J, O'Rahilly S. Regulation of tumour necrosis factor-alpha release from human adipose tissue in vitro. J Endocrinol 1999; 163(1):33-38.

111. Peraldi P, Xu M, Spiegelman BM. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J Clin Invest 1997; 100(7):1863-1869.

112. Morin CL, Eckel RH, Marcel T, Pagliassotti MJ. High fat diets elevate adipose tissue-derived tumor necrosis factor- alpha activity. Endocrinology 1997; 138(11):4665-4671.

113. Ruan H, Hacohen N, Golub TR, Parijs L van, Lodish HF. Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory. Diabetes 2002; 51(5):1319-1336.

114. Hotamisligil GS. Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes Relat Metab Disord 2000; 24 Suppl 4:S23-S27.

115. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259(5091):87-91.

116. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF- alpha function. Nature 1997; 389(6651):610-614.

117. Sethi JK, Hotamisligil GS. The role of TNF alpha in adipocyte metabolism. Semin Cell Dev Biol 1999; 10(1):19-29.

118. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95(5):2409-2415.

119. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95(5):2111-2119.

120. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82(12):4196-4200.

121. Pfeiffer A, Janott J, Mohlig M, Ristow M, Rochlitz H, Busch K et al. Circulating tumor necrosis factor alpha is elevated in male but not in female patients with type II diabetes mellitus. Horm Metab Res 1997; 29(3):111-114.

122. Lofgren P, Harmelen V van, Reynisdottir S, Naslund E, Ryden M, Rossner S et al. Secretion of tumor necrosis factor-alpha shows a strong relationship to insulin-stimulated glucose transport in human adipose tissue. Diabetes 2000; 49(5):688-692.

123. Kellerer M, Rett K, Renn W, Groop L, Haring HU. Circulating TNF-alpha and leptin levels in offspring of NIDDM patients do not correlate to individual insulin sensitivity. Horm Metab Res 1996; 28(12):737-743.

124. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996; 45(7):881-885.

125. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNF alpha by human muscle. Relationship to insulin resistance. J Clin Invest 1996; 97(4):1111-1116.

126. Dietze D, Koenen M, Rohrig K, Horikoshi H, Hauner H, Eckel J. Impairment of insulin signaling in human skeletal muscle cells by co- culture with human adipocytes. Diabetes 2002; 51(8):2369-2376.

127. Snick J van. Interleukin-6: an overview. Annu Rev Immunol 1990; 8:253-278.

128. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998; 83(3):847-850.

129. Greenberg AS, Nordan RP, McIntosh J, Calvo JC, Scow RO, Jablons D. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res 1992; 52(15):4113-4116.

130. Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 1998; 22(12):1145-1158.

131. Vicennati V, Vottero A, Friedman C, Papanicolaou DA. Hormonal regulation of interleukin-6 production in human adipocytes. Int J Obes Relat Metab Disord 2002; 26(7):905-911.

132. Mohamed-Ali V, Flower L, Sethi J, Hotamisligil G, Gray R, Humphries SE et al. beta-Adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies. J Clin Endocrinol Metab 2001; 86(12):5864-5869.

133. Nakajima K, Matsuda T, Fujitani Y, Kojima H, Yamanaka Y, Nakae K et al. Signal transduction through IL-6 receptor: involvement of multiple protein kinases, stat factors, and a novel H7-sensitive pathway. Ann N Y Acad Sci 1995; 762:55-70.

134. Stouthard JM, Romijn JA, Pol T van der, Endert E, Klein S, Bakker PJ et al. Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol 1995; 268(5 Pt 1):E813-E819.

135. Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 1997; 82(12):4167-4170.

136. Nonogaki K, Fuller GM, Fuentes NL, Moser AH, Staprans I, Grunfeld C et al. Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 1995; 136(5):2143-2149.

137. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280(5):E745-E751.

138. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000; 85(9):3338-3342.

139. Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105(7):804-809.

140. Bastard JP, Maachi M, Nhieu JT van, Jardel C, Bruckert E, Grimaldi A et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 2002; 87(5):2084-2089.

141. Fernandez-Real JM, Broch M, Vendrell J, Gutierrez C, Casamitjana R, Pugeat M et al. Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes 2000; 49(3):517-520.

142. Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 2000; 67(3):291-300.

143. Kanemaki T, Kitade H, Kaibori M, Sakitani K, Hiramatsu Y, Kamiyama Y et al. Interleukin 1beta and interleukin 6, but not tumor necrosis factor alpha, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes. Hepatology 1998; 27(5):1296-1303.

144. Stouthard JM, Oude Elferink RP, Sauerwein HP. Interleukin-6 enhances glucose transport in 3T3-L1 adipocytes. Biochem Biophys Res Commun 1996; 220(2):241-245.

145. Febbraio MA, Pedersen BK. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J 2002; 16(11):1335-1347.

146. Ross R, Aru J, Freeman J, Hudson R, Janssen I. Abdominal adiposity and insulin resistance in obese men. Am J Physiol Endocrinol Metab 2002; 282(3):E657-E663.

147. Brochu M, Starling RD, Tchernof A, Matthews DE, Garcia-Rubi E, Poehlman ET. Visceral adipose tissue is an independent correlate of glucose disposal in older obese postmenopausal women. J Clin Endocrinol Metab 2000; 85(7):2378-2384.

148. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987; 36(1):54-59.

149. Park KS, Rhee BD, Lee KU, Kim SY, Lee HK, Koh CS et al. Intra-abdominal fat is associated with decreased insulin sensitivity in healthy young men. Metabolism 1991; 40(6):600-603.

150. Gabriely I, Ma XH, Yang XM, Atzmon G, Rajala MW, Berg AH et al. Removal of Visceral Fat Prevents Insulin Resistance and Glucose Intolerance of Aging: An Adipokine-Mediated Process? Diabetes 2002; 51(10):2951-2958.

151. Gautier JF, Mourier A, Kerviler E de, Tarentola A, Bigard AX, Villette JM et al. Evaluation of abdominal fat distribution in noninsulin-dependent diabetes mellitus: relationship to insulin resistance. J Clin Endocrinol Metab 1998; 83(4):1306-1311.

152. Bjorntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990; 10(4):493-496.

153. Randle PJ, Garland PB, Hales CJ et al. The glucose fatty acid cycle: its role in insulin sensitivity and metabolic disturbances of diabetes mellitus. 7285-7289. 1963.

154. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest 1995; 96(1):88-98.

155. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Adams-Huet B, Grundy SM. Relationship of generalized and regional adiposity to insulin sensitivity in men with NIDDM. Diabetes 1996; 45(12):1684-1693.

156. Smith SR, Lovejoy JC, Greenway F, Ryan D, Jonge L de, Bretonne J de la et al. Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. Metabolism 2001; 50(4):425-435.

157. Goodpaster BH, Theriault R, Watkins SC, Kelley DE. Intramuscular lipid content is increased in obesity and decreased by weight loss. Metabolism 2000; 49(4):467-472.

158. Kelley DE, Goodpaster BH, Storlien L. Muscle triglyceride and insulin resistance. Annu Rev Nutr 2002; 22:325-346.

159. Krssak M, Falk PK, Dresner A, DiPietro L, Vogel SM, Rothman DL et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 1999; 42(1):113-116.

160. Frayn KN. Adipose tissue and the insulin resistance syndrome. Proc Nutr Soc 2001; 60(3):375-380.

161. Garg A. Lipodystrophies. Am J Med 2000; 108(2):143-152.

162. Ravussin E, Smith SR. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann N Y Acad Sci 2002; 967:363-378.

163. Garg A, Misra A. Hepatic steatosis, insulin resistance, and adipose tissue disorders. J Clin Endocrinol Metab 2002; 87(7):3019-3022.

164. Dobbins RL, Szczepaniak LS, Bentley B, Esser V, Myhill J, McGarry JD. Prolonged inhibition of muscle carnitine palmitoyltransferase-1 promotes intramyocellular lipid accumulation and insulin resistance in rats. Diabetes 2001; 50(1):123-130.

165. Agarwal AK, Arioglu E, Almeida S de, Akkoc N, Taylor SI, Bowcock AM et al. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat Genet 2002; 31(1):21-23.

166. Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359(9311):1026-1031.

167. Zumbach MS, Boehme MW, Wahl P, Stremmel W, Ziegler R, Nawroth PP. Tumor necrosis factor increases serum leptin levels in humans. J Clin Endocrinol Metab 1997; 82(12):4080-4082.

168. Gottschling-Zeller H, Birgel M, Scriba D, Blum WF, Hauner H. Depot-specific release of leptin from subcutaneous and omental adipocytes in suspension culture: effect of tumor necrosis factor-alpha and transforming growth factor-beta1. Eur J Endocrinol 1999; 141(4):436-442.

169. Grunfeld C, Zhao C, Fuller J, Pollack A, Moser A, Friedman J et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest 1996; 97(9):2152-2157.

170. Heim MH. The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus. J Recept Signal Transduct Res 1999; 19(1-4):75-120.

171. Kim YB, Uotani S, Pierroz DD, Flier JS, Kahn BB. In vivo administration of leptin activates signal transduction directly in insulin-sensitive tissues: overlapping but distinct pathways from insulin. Endocrinology 2000; 141(7):2328-2339.